Cerlapirdine

Cerlapirdine
Systematic (IUPAC) name
	N,N-dimethyl-3-{[3-(naphthalen-1-ylsulfonyl)-2H-indazol-5-yl]oxy}propan-1-amine
Clinical data
Pregnancy cat.	?
Legal status	Non-regulated
Identifiers
CAS number	925448-93-7; 925447-04-7 (hydrochloride)
ATC code	None
PubChem	CID 16071605
ChemSpider	17231095
Chemical data
Formula	C22H23N3O3S
Mol. mass	409.501 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24); Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N ;

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.^[1] As of 2011, it is in phase II clinical trials, and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events.^[2] It exerts its effects by acting as a selective 5-HT₆ receptor antagonist.^[1]

[edit] See also